Oculis (NASDAQ:OCS) Sets New 1-Year High – Here’s Why

Oculis Holding AG (NASDAQ:OCS)’s share price hit a new 52-week high on Thursday . The stock traded as high as $26.89 and last traded at $26.04, with a volume of 384101 shares changing hands. The stock had previously closed at $26.00.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Oculis in a research note on Friday, December 19th. They issued an “overweight” rating and a $38.00 price target for the company. Bank of America reduced their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Lifesci Capital began coverage on shares of Oculis in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target on the stock. Finally, Stifel Nicolaus increased their price objective on shares of Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a report on Friday, December 19th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.50.

Oculis Stock Up 1.6%

The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.47 and a current ratio of 4.47. The stock’s fifty day simple moving average is $21.05 and its two-hundred day simple moving average is $19.38. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -10.77 and a beta of 0.31.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The company had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. On average, sell-side analysts anticipate that Oculis Holding AG will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

Hedge funds have recently modified their holdings of the stock. Aberdeen Group plc lifted its holdings in shares of Oculis by 39.4% during the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after purchasing an additional 493,827 shares during the last quarter. Compagnie Lombard Odier SCmA raised its holdings in Oculis by 10.6% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock worth $2,143,000 after buying an additional 10,300 shares during the period. Syquant Capital Sas purchased a new stake in Oculis during the fourth quarter valued at about $3,849,000. Aventura Private Wealth LLC acquired a new position in shares of Oculis in the fourth quarter worth about $80,000. Finally, Woodline Partners LP increased its position in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares in the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.